Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Specimen Handling 3Blood Specimen Collection 2somapacitan 1pembrolizumab 1ibrutinib 1gallium 68 PSMA-11 1fluorodopa F 18 1exemestane 1durvalumab 1Tumor Burden 1Telemedicine 1Tamoxifen 1Standard of Care 1Semen Analysis 1Radiography, Panoramic 1Protons 1Physical Examination 1Photons 1Music Therapy 1Magnetic Resonance Spectroscopy 1Letrozole 1JNJ-64619178 1JNJ-64264681 1High-Intensity Interval Training 1Exercise 1Esophagectomy 1Electrocardiography 1Community Health Workers 1Angptl4 protein, mouse 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Neoplasms × JNJ-64264681 × Clear all
NCT06788509 2026-06-05

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Janssen Research & Development, LLC

Phase 1 Enrolling by invitation
120 enrolled
GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡